<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="9f8fba65-91b4-4395-b801-ef69e98eabd1"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION 1.25% safely and effectively. See full prescribing information for Â PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION 1.25%.<br/>
         <br/>
      </content>
      <content styleCode="bold">PILOCARPINE HYDROCHLORIDE ophthalmic solution 1.25%, for topical ophthalmic use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1974<br/>
         <br/>
      </content>
   </title>
   <effectiveTime value="20250502"/>
   <setId root="93e37b61-7b90-4740-b0b4-17d39d3b03f6"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals NY LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="860156658" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60219-2366" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60219-2366" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60219-2366" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="sterilize" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60219-2366" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="93fb88df-f591-4dbb-be16-47043fc6e808"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250502"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60219-2366" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Pilocarpine Hydrochloride Ophthalmic</name>
                        <formCode code="C60992" displayName="SOLUTION/ DROPS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Pilocarpine Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0WW6D218XJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PILOCARPINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="01MI4Q9DI3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PILOCARPINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="60219-2366-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250501"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217733" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250501"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" displayName="OPHTHALMIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">
               <id root="60795a96-3bb3-44a1-80d6-622a2b69149d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Pilocarpine hydrochloride ophthalmic solution is indicated for the treatment of presbyopia in adults. </paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pilocarpine hydrochloride is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults. (<linkHtml href="#LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">
               <id root="4b1264b8-70a9-4f4f-9e94-1f37bb296196"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended dosage of pilocarpine hydrochloride ophthalmic solution is one drop in each eye once daily.</paragraph>
                  <paragraph>If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill one drop of pilocarpine hydrochloride ophthalmic solution 1.25% in each eye once daily. (<linkHtml href="#LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">2</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">
               <id root="d64ffa01-0d72-4379-9bb0-745e6023ecf8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Pilocarpine hydrochloride ophthalmic solution, USP is a clear, colorless, sterile ophthalmic solution containing 1.25% (12.5 mg/mL) of pilocarpine hydrochloride. </paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing pilocarpine hydrochloride USP, 1.25%. (<linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">
               <id root="b5174d18-9b58-4a69-8fa2-2716be9ae81f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Pilocarpine hydrochloride ophthalmic solution is contraindicated in patients with known hypersensitivity to the active ingredient or to any of the excipients.</paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity. (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_4e1684e1-bdaa-4046-ac6f-e2816f5fb48e">
               <id root="e9176b8d-1f2f-4725-9e6f-870b88b1fd21"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Blurred Vision</content>: Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous activities in poor illumination. (<linkHtml href="#LINK_a3f36542-85e7-4a3a-b292-b0d1726a7ee0">5.1</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk of Retinal Detachment</content>: Rare cases of retinal detachment and retinal tear have been reported with miotics, including pilocarpine hydrochloride ophthalmic solution. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters or vision loss. (<linkHtml href="#LINK_54839cb3-4c5d-480e-a9a0-51b76cbc3405">5.2</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Iritis</content>: Caution is advised in patients with iritis. (<linkHtml href="#LINK_60d14928-efd2-40e6-93fe-5c150d1d0db7">5.3</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_a3f36542-85e7-4a3a-b292-b0d1726a7ee0">
                     <id root="48f2edb3-deb5-4c5b-b645-c62d5c965913"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1
Blurred Vision</title>
                     <text>
                        <paragraph>Miotics, including pilocarpine hydrochloride ophthalmic solution, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision).</paragraph>
                        <paragraph>In addition, patients may experience temporary dim or dark vision with miotics, including pilocarpine hydrochloride ophthalmic solution. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_54839cb3-4c5d-480e-a9a0-51b76cbc3405">
                     <id root="1038d3df-3488-4f9e-9773-e70122bb7de7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Risk of Retinal Detachment</title>
                     <text>
                        <paragraph>Rare cases of retinal detachment and retinal tear have been reported with miotics, including pilocarpine hydrochloride ophthalmic solution.</paragraph>
                        <paragraph>Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy.<br/>
                        </paragraph>
                        <paragraph>Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters or vision loss.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_60d14928-efd2-40e6-93fe-5c150d1d0db7">
                     <id root="41ff7c04-0320-4f75-adfe-b713f1480187"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Iritis</title>
                     <text>
                        <paragraph>Pilocarpine hydrochloride ophthalmic solution is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and the lens. </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_73e4c250-9273-4a28-a3f8-2ae6e536f226">
                     <id root="86a65a70-9526-4563-9357-444cdeab5815"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Use with Contact Lenses</title>
                     <text>
                        <paragraph>Contact lens wearers should be advised to remove their lenses prior to the instillation of pilocarpine hydrochloride ophthalmic solution and to wait 10 minutes after dosing before reinserting their contact lenses.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_847fbd13-edad-424a-83d0-10d29861ffac">
                     <id root="c8b967c3-d5fd-46bb-aa36-2deadb9f91ed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Potential for Eye Injury or
Contamination</title>
                     <text>
                        <paragraph>To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface. </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9440e503-baf7-441c-991f-439bc85d32c3">
               <id root="f4311870-8b97-4522-833e-6304f55fabd4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in labeling: </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Hypersensitivity <content styleCode="italics">[see <content styleCode="italics">
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (</linkHtml>
                              </content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4)</linkHtml>
                              </content>
                           </content>] </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (&gt; 5%) are headache, conjunctival hyperemiaÂ and eye irritation. (<linkHtml href="#LINK_fbc90c1d-5063-43c1-9d8a-b9bf711f71d5">6.1</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.Â <br/>
                              <br/>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_fbc90c1d-5063-43c1-9d8a-b9bf711f71d5">
                     <id root="68c8409a-0710-4dcd-9ab2-dd2777b6e4dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1
Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>Pilocarpine hydrochloride ophthalmic solution dosed once dailyÂ was evaluated in 375 participantsÂ with presbyopia in two randomized, double-masked, vehicle-controlled studies (GEMINI 1 and GEMINI 2) of 30 days duration. The most common adverse reactions reported in &gt; 5% of participantsÂ were headache and conjunctival hyperemia. Ocular adverse reactions reported in 1% to 5% of participantsÂ were blurred vision, eye pain, visual impairment, eye irritation and increased lacrimation.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_257fd363-568f-4e4a-a521-42c57079e020">
                     <id root="c1702871-80b4-4cbc-8f8c-5e7f6ae24823"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post-marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of pilocarpine hydrochloride ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to pilocarpine hydrochloride ophthalmic solution exposure. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye disorders: </content>vitreous detachment, vitreomacular traction, retinal tear, retinal detachment.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d8fb27d1-edc0-46b8-9cc1-d87f6735066d">
               <id root="8cb3f00e-1224-4c1f-bd78-d04f54c5302e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250502"/>
               <component>
                  <section ID="LINK_c7ddff79-330d-427b-b47b-400ef0464579">
                     <id root="ca1fe5e1-5915-4c40-807f-23bd9809671d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies of pilocarpine hydrochloride ophthalmic solution administration in pregnant women to inform a drug-associated risk. Oral administration of pilocarpine to pregnant rats throughout organogenesis and lactation did not produce adverse effects at clinically relevant doses.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                           <br/>
                        </paragraph>
                        <paragraph>No adequate and well-controlled trials of pilocarpine hydrochloride ophthalmic solution have been conducted in pregnant women. In a retrospective case series of 15 women with glaucoma, 4 patients used ophthalmic pilocarpine either pre-pregnancy, during pregnancy or postpartum. There were no adverse effects observed in patients or in their infants.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                           <br/>
                        </paragraph>
                        <paragraph>In embryofetal development studies, oral administration of pilocarpine to pregnant rats throughout organogenesis produced maternal toxicity, skeletal anomalies and reduction in fetal body weight at 90 mg/kg/day (approximately 485-fold higher than the maximum human ophthalmic dose [MHOD] of 0.015 mg/kg/day, on a mg/m<sup>2 </sup>basis).<br/>
                        </paragraph>
                        <paragraph>In a peri-/postnatal study in rats, oral administration of pilocarpine during late gestation through lactation increased stillbirths at a dose of 36 mg/kg/day (approximately 195-fold higher than the MHOD). Decreased neonatal survival and reduced mean body weight of pups were observed at â¥ 18 mg/kg/day (approximately 100 times the maximum human ophthalmic dose of pilocarpine hydrochloride ophthalmic solution).<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">
                     <id root="7e5c9d32-ca0a-48c8-b5e0-2f262e175876"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of pilocarpine in human milk, the effects on the breastfed infants, or the effects on milk production to inform risk of pilocarpine hydrochloride ophthalmic solution to an infant during lactation.</paragraph>
                        <paragraph>Pilocarpine and/or its metabolites are excreted in the milk of lactating rats. Systemic levels of pilocarpine following topical ocular administration are low <content styleCode="italics">[see <content styleCode="italics">
                                 <content styleCode="italics">
                                    <linkHtml href="#LINK_40da22ab-9880-419c-aac4-3222230c217b">Clinical Pharmacology (</linkHtml>
                                 </content>
                                 <content styleCode="italics">
                                    <linkHtml href="#LINK_40da22ab-9880-419c-aac4-3222230c217b">12.3)</linkHtml>
                                 </content>
                              </content>]</content> and it is not known whether measurable levels of pilocarpine would be present in maternal milk following topical ocular administration.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for pilocarpine hydrochloride ophthalmic solution and any potential adverse effects on the breastfed child from pilocarpine hydrochloride ophthalmic solution.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Following a single oral administration of <sup>14</sup>C-pilocarpine to lactating rats, the radioactivity concentrations in milk were similar to those in plasma.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2a76746e-04aa-4ca6-8470-1aa0e68d79ac">
                     <id root="abf4da93-6cdf-4125-bc56-d1e532e5d841"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Presbyopia does not occur in the pediatric population. </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">
                     <id root="3f247f80-9c7f-4bef-a572-f4d29a337a8e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of pilocarpine hydrochloride ophthalmic solution did not include participants aged 65 and over to determine whether they respond differently from younger participants. Other reported clinical experience with ophthalmic pilocarpine solutions have not identified overall differences in safety between elderly and younger participants. </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_7672321b-456b-49d1-95e6-3b804a643ebe">
               <id root="4c9dec84-df63-4034-987e-2cfc0f60168b"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Systemic toxicity following topical ocular administration of pilocarpine is rare, but occasionally patients who are sensitive may develop sweating and gastrointestinal overactivity. Accidental ingestion can produce sweating, salivation, nausea, tremors and slowing of the pulse and a decrease in blood pressure. In moderate overdosage, spontaneous recovery is to be expected and is aided by intravenous fluids to compensate for dehydration. For patients demonstrating severe poisoning, atropine, the pharmacologic antagonist to pilocarpine, should be used. </paragraph>
               </text>
               <effectiveTime value="20250502"/>
            </section>
         </component>
         <component>
            <section ID="LINK_94dfdaa6-3893-42c2-9260-ca4a11462f2f">
               <id root="79ff00c9-d0df-41d4-b352-97c36449150e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Pilocarpine hydrochloride ophthalmic solution USP, 1.25% is a cholinergic muscarinic receptor agonist prepared as an isotonic, clear, colorless, sterile ophthalmic solution containing 1.25% of pilocarpine hydrochloride, USP. The chemical name for pilocarpine hydrochloride, USP is (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]-oxolan-2-one hydrochloride. Its molecular weight is 244.72 g/mol and its molecular formula is C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> Â· HCl. Its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Pilocarpine hydrochloride, USP is a white or almost white, crystalline powder or colorless crystals hygroscopic. It is very soluble in water and freely soluble in alcohol, slightly soluble in chloroform and insoluble in ether.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL of Pilocarpine Hydrochloride Ophthalmic Solution, USP contains:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active:</content> Pilocarpine hydrochloride USP, 1.25% (12.5 mg) equivalent to 1.06% (10.6 mg) pilocarpine free-base.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative:</content> Benzalkonium chloride, 0.0075%.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactives:</content> Boric acid, sodium citrate dihydrate, sodium chloride, water for injection and may also include hydrochloric acid and/or sodium hydroxide for pH adjustment to between 3.5 and 5.5, if necessary.</paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pilocarpine-hydrochloride-ophthalmic-solution-usp-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bccb04cc-3991-4ea2-b6f4-04a6afd0b8f3">
               <id root="ae1584d5-a655-405f-b895-abd6de4255be"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250502"/>
               <component>
                  <section ID="LINK_f1abae1d-7871-43d7-bbb1-77ffe4b1ffb5">
                     <id root="8f01afcd-b013-440d-814f-85167daf86ac"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Pilocarpine hydrochloride is a cholinergic muscarinic agonist which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle. Pilocarpine hydrochloride contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light. Pilocarpine hydrochloride also contracts the ciliary muscle and may shift the eye to a more myopic state. </paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_40da22ab-9880-419c-aac4-3222230c217b">
                     <id root="c3138859-4eb3-4a81-95f6-ce12118756da"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Systemic exposure to pilocarpine was evaluated in 22 participants with presbyopia who were administered 1 drop of pilocarpine hydrochloride ophthalmic solution in each eye once daily for 30 days (GEMINI 1). The mean (SD) C<sub>max</sub> and AUC values from time 0 to last measurable concentration over 10-hour period post-last dose on Day 30 were 1.95 (0.98) ng/mL and 4.14 (2.16) ngÂ·hr/mL, respectively. The median T<sub>max</sub> value on Day 30 was 0.3 hours post-dose with a range from 0.2 hours to 0.5 hours post-dose.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5daa79e6-a212-4003-bec5-c4661f04ac51">
               <id root="e07f895f-f470-44b3-a3e8-3139f366f55e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250502"/>
               <component>
                  <section ID="LINK_de7b6a6c-102a-443a-8563-e9fb72cae2d9">
                     <id root="986ed463-f8ac-4c13-8077-9820b2c0d839"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis </content>
                        </paragraph>
                        <paragraph>Pilocarpine did not induce tumors in mice at any dosage level studied (up to 30 mg/kg/day; approximately 80-times the MHOD). In rats, an oral dose of 18 mg/kg/day (approximately 100 times the MHOD), resulted in a statistically significant increase in the incidence of benign pheochromocytomas in both male and female rats and a statistically significant increase in the incidence of hepatocellular adenomas in female rats.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Pilocarpine did not show any potential to cause genetic toxicity in a series of studies that included:</paragraph>
                        <paragraph>1) bacterial assays (Salmonella and E. coli) for reverse gene mutations. </paragraph>
                        <paragraph>2) an <content styleCode="italics">in vitro</content> chromosome aberration assay in a Chinese hamster ovary cell line. </paragraph>
                        <paragraph>3) an <content styleCode="italics">in vivo</content> chromosome aberration assay (micronucleus test) in mice; and</paragraph>
                        <paragraph>4) a primary DNA damage assay (unscheduled DNA synthesis) in rat hepatocyte primary cultures. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Pilocarpine oral administration to male and female rats at a dosage of 18 mg/kg/day (100 times the MHOD) resulted in impaired reproductive function, including reduced fertility, decreased sperm motility and morphologic evidence of abnormal sperm. It is unclear whether the reduction in fertility was due to effects on males, females or both. In dogs, exposure to pilocarpine at a dosage of 3 mg/kg/day for 6 months resulted in evidence of impaired spermatogenesis (approximately 55 times the MHOD).</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_995374a6-9348-42d8-aeae-912d8e71b14b">
               <id root="6ee6e215-48e6-418d-919a-a25f2975d4fe"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of pilocarpine hydrochloride ophthalmic solution dosed once dailyÂ for the treatment of presbyopia was demonstrated in two 30-Day Phase 3, randomized, double-masked, vehicle-controlled studies, namely GEMINI 1 (NCT03804268) and GEMINI 2 (NCT03857542). A total of 750 participants aged 40 years to 55 years old with presbyopia were randomized (375 to pilocarpine hydrochloride ophthalmic solution group) in two studies and participants were instructed to administer one drop of pilocarpine hydrochloride ophthalmic solution or vehicle once daily in each eye. </paragraph>
                  <paragraph>In both studies, the proportion of participants gaining 3 lines or more in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA), without losing more than 1 line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction was statistically significantly greater in the Â pilocarpine hydrochloride group compared to the vehicle group at Day 30, Hour 3 (see Table 1).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 1: Primary Efficacy Results from GEMINI 1 and GEMINI 2 Studies (Intent-to-Treat Population)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Â </content>
                  </paragraph>
                  <table width="100%" cellspacing="0" cellpadding="0" border="1">
                     <col width="100px"/>
                     <col width="100px"/>
                     <col width="100px"/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" valign="top" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">GEMINI 1</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">GEMINI 2</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Pilocarpine Hydrochloride Ophthalmic Solution</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=163</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=160</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">p-value</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Pilocarpine Hydrochloride Ophthalmic Solution</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=212</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=215</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">p-value</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Proportion of participants gaining 3-lines or more in mesopic DCNVA, without losing more than 1 line (5 letters) of CDVA at Day 30, Hour 3 </paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>31%</paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>8%</paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>p &lt; 0.01</paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>26%</paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>11%</paragraph>
                           </td>
                           <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>p &lt; 0.01</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> Figures 1 and 2 present the proportion of participants who gained 3-lines or more in mesopic DCNVA at Day 30.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Proportion of Participants Achieving 3-Lines or More Improvement in Mesopic, High Contrast, Binocular DCNVA at Day 30 in GEMINI 1 (Intent-to-Treat Population)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM2"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2: Proportion of Participants Achieving 3-lines or More Improvement in Mesopic, High Contrast, Binocular DCNVA at Day 30 in GEMINI 2 (Intent-to-Treat Population)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM3"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pilocarpine-hydrochloride-ophthalmic-solution-usp-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pilocarpine-hydrochloride-ophthalmic-solution-usp-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a0b45d85-af35-4ea1-b85b-0827eb4c813b">
               <id root="8c3beca2-e671-4e1e-bd48-7c366b8ab486"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Pilocarpine Hydrochloride Ophthalmic Solution USP, <content styleCode="bold">1.25% </content>is supplied as a sterile, clear, colorless solution filled in low density polyethylene white opaque bottle and low density polyethylene white opaque nozzle with, dark green colored high density polyethylene cap. It is available as follows:</paragraph>
                  <paragraph>2.5 mL in 5 mL Bottle (Filled to 1/2 Capacity): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 60219-2366-2</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at 15Â° to 25Â°C (59Â° to 77Â°F). After opening, pilocarpine hydrochloride ophthalmic solution, USP can be used until the expiration date on the bottle.</paragraph>
               </text>
               <effectiveTime value="20250502"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7f1499bb-6eb0-433e-ad99-1e4cdeab02da">
               <id root="b8a9e290-9184-4afc-9403-4147bb8f7691"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Night Driving</content>
                  </paragraph>
                  <paragraph>Pilocarpine hydrochloride ophthalmic solution may cause temporary dim or dark vision. Advise patients to exercise caution with night driving and when hazardous activities are undertaken in poor illumination <content styleCode="italics">[see <linkHtml href="#LINK_a3f36542-85e7-4a3a-b292-b0d1726a7ee0">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Accommodative Spasm</content>
                  </paragraph>
                  <paragraph>Temporary problems when changing focus between near and distant objects may occur. Advise patients not to drive or use machinery if vision is not clear (e.g., blurred vision) <content styleCode="italics">[see <linkHtml href="#LINK_a3f36542-85e7-4a3a-b292-b0d1726a7ee0">Warnings and Precautions (5.1)</linkHtml>]</content>.<content styleCode="italics">Â Â </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">When to Seek Physician Advice</content>
                  </paragraph>
                  <paragraph>Advise patients to seek immediate medical care with sudden onset of flashing lights, floaters or vision loss <content styleCode="italics">[see <linkHtml href="#LINK_54839cb3-4c5d-480e-a9a0-51b76cbc3405">Warnings and Precautions (5.2)</linkHtml>]</content>.<content styleCode="italics">Â Â </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Contact Lens Wear</content>
                  </paragraph>
                  <paragraph>Contact lens should be removed prior to the instillation of pilocarpine hydrochloride ophthalmic solution. Wait 10 minutes after dosing before reinserting contact lenses <content styleCode="italics">[see <content styleCode="italics">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_73e4c250-9273-4a28-a3f8-2ae6e536f226">Warnings and Precautions (</linkHtml>
                           </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_73e4c250-9273-4a28-a3f8-2ae6e536f226">5.4)</linkHtml>
                           </content>
                        </content>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Avoiding Contamination of the Product</content>
                  </paragraph>
                  <paragraph>Do not touch dropper tip to any surface, as this may contaminate the contents <content styleCode="italics">[see <content styleCode="italics">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_847fbd13-edad-424a-83d0-10d29861ffac">Warnings and Precautions (</linkHtml>
                           </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_847fbd13-edad-424a-83d0-10d29861ffac">5.5)</linkHtml>
                           </content>
                        </content>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Concomitant Topical Ocular Therapy</content>
                  </paragraph>
                  <paragraph>If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals Pvt. Ltd.</content>
                  </paragraph>
                  <paragraph> Ahmedabad 382213, INDIA</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Â </content>Bridgewater, NJ 08807</paragraph>
                  <paragraph>Rev. 05-2025-00</paragraph>
               </text>
               <effectiveTime value="20250502"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3d87df18-2dda-4d16-b4be-ede5d6584ea0">
               <id root="1bcd2c4f-4765-498a-a668-75940f5b973d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">NDC 60219-2366-2</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Pilocarpine Hydrochloride Ophthalmic Solution USP,Â </content>
                        <content styleCode="bold">1.25% (2.5 mL)</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">
                           <content styleCode="bold">
                              <content styleCode="bold">Rx onl</content>
                           </content>
                        </content>
                     </content>
                     <content styleCode="bold">y</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM4"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Â </content>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pilocarpine-hydrochloride-ophthalmic-solution-usp-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pilocarpine-hydrochloride-ophthalmic-solution-usp-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>